These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 16280337)

  • 1. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?
    Gough SC; O'Donovan MC
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):47-55. PubMed ID: 16280337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risperidone-related weight gain: genetic and nongenetic predictors.
    Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
    J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Association of antipsychotic agent-induced weight gain with a polymorphism of the promotor region of the 5-HT2C receptor gene].
    Zhang Z; Zhang X; Yao Z; Chen J; Sun J; Yao H; Hou G; Zhang X; Reynolds GP
    Zhonghua Yi Xue Za Zhi; 2002 Aug; 82(16):1097-101. PubMed ID: 12425817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. -759 C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment.
    Ryu S; Cho EY; Park T; Oh S; Jang WS; Kim SK; Lee D; Hong KS
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Apr; 31(3):673-7. PubMed ID: 17275977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipsychotic-induced weight gain--pharmacogenetic studies].
    Olajossy-Hilkesberger L; Godlewska B; Marmurowska-Michałowskal H; Olajossy M; Landowski J
    Psychiatr Pol; 2006; 40(5):1009-20. PubMed ID: 17217242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comorbidity of diabetes mellitus and psychiatric disorders.
    Medved V; Jovanović N; Knapić VP
    Psychiatr Danub; 2009 Dec; 21(4):585-8. PubMed ID: 19935498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes and schizophrenia 2005: are we any closer to understanding the link?
    Holt RI; Bushe C; Citrome L
    J Psychopharmacol; 2005 Nov; 19(6 Suppl):56-65. PubMed ID: 16280338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?
    Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM
    Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for the study of the genetic determinants of diabetes and its complications.
    Doria A
    Przegl Lek; 2000; 57 Suppl 3():7-12. PubMed ID: 11293232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population.
    Ji X; Takahashi N; Saito S; Ishihara R; Maeno N; Inada T; Ozaki N
    Neurosci Lett; 2008 Apr; 435(2):95-8. PubMed ID: 18359159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006 Nov; 67(11):e16. PubMed ID: 17201046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absence of weight gain association with the HTR2C -759C/T polymorphism in patients with schizophrenia treated with iloperidone.
    Thompson A; Lavedan C; Volpi S
    Psychiatry Res; 2010 Feb; 175(3):271-3. PubMed ID: 20045196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Schizophrenia, the metabolic syndrome and diabetes.
    Holt RI; Peveler RC; Byrne CD
    Diabet Med; 2004 Jun; 21(6):515-23. PubMed ID: 15154933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics.
    Ferentinos P; Dikeos D
    Curr Opin Psychiatry; 2012 Sep; 25(5):381-90. PubMed ID: 22842659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia.
    Zhang ZJ; Zhang XB; Sha WW; Zhang XB; Reynolds GP
    Mol Psychiatry; 2002; 7(7):670-1. PubMed ID: 12192608
    [No Abstract]   [Full Text] [Related]  

  • 17. Medical risk in patients with bipolar disorder and schizophrenia.
    Newcomer JW
    J Clin Psychiatry; 2006; 67 Suppl 9():25-30; discussion 36-42. PubMed ID: 16965186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study of 5-HT related genes as possible etiological agents in schizophrenia].
    Ozaki N
    Seishin Shinkeigaku Zasshi; 2002; 104(6):501-8. PubMed ID: 12373805
    [No Abstract]   [Full Text] [Related]  

  • 20. Genome-wide association study for type 2 diabetes: clinical applications.
    Lyssenko V; Groop L
    Curr Opin Lipidol; 2009 Apr; 20(2):87-91. PubMed ID: 19276887
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.